Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of active relapsing-remitting multiple sclerosis (MS). Alemtuzumab induces a rapid and prolonged depletion of lymphocytes from the circulation, which results in a profound immuno-suppression status followed by an i...

Full description

Saved in:
Bibliographic Details
Published in:Front Endocrinol (Lausanne)
Main Authors: Rotondi, Mario, Molteni, Martina, Leporati, Paola, Capelli, Valentina, Marinò, Michele, Chiovato, Luca
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2017
Subjects:
Endocrinology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626941/
https://ncbi.nlm.nih.gov/pubmed/29033895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2017.00254
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items